2022 International Congress of Diabetes and Metabolism

S3 Diabetes complications 1 : Heart failure in diabetes: from mechanisms to management	09:00~11:00 / Friday 7 October Convention Hall C, 4F Chairman:Soonjib Yoo, Young Il Kim	Overview
Type 2 diabetes is one of the most relevant risk factors for heart failure. The prevalence of heart failure in general population and heart failure in patients with type 2 diabetes mellitus is increasing worldwide. Although the concept of a diabetic cardiomyopathy is now well established, a complex underlying, and interrelated pathophysiology exists in heart failure of patients with type 2 diabetes mellitus. Beyond glycemic control, multifactorial Intervention was needed in patients with heart failure and diabetes. The aim of the session is to highlight the current perspectives from the pathophysiology to the management of heart failure in pertains to type 2 diabetes.
Chan Joo Lee Yonsei University, Korea	S3-1Diabetic cardiomyopathy: translating mechanistic insights into practice
Javed Butler Baylor Scott and White Research Institute, USA	S3-2Heart failure in type 2 diabetes: current perspectives on screening and diagnosis
Mark Cooper Monash University, Australia	S3-3The role of SGLT2 inhibitors in cardiorenal syndrome: to diabetes and beyond
Eun-Jung Rhee Sungkyunkwan University, Korea	S3-4An integrated approach to managing heart failure in patients with diabetes

S12 Diabetes complications 2 : Sarcopenia: a chronic complication of T2DM	09:00~11:00 / Saturday 8 October Convention Hall C, 4F Chairman:Jeong Hyun Park, Kyu Jeung Ahn	Overview
Type 2 diabetes is at increased risk for low muscle mass and impaired strength and mobility, frequently related to the disease control. This session titled, ‘Sarcopenia: a chronic complication of type 2 diabetes’ is a clinical session designed to provide recent evidence for clinicians and researchers on how to care for patients with type 2 diabetes and frailty. In this session, experts from each field of sarcopenia will deliver the latest knowledge on sarcopenia, share the bidirectional relationship between type 2 diabetes and sarcopenia, and highlight current research gaps and treatments.
Kyoung Min Kim Yonsei University, Korea	S12-1Sarcopenia in Korea: prevalence and clinical aspects
David Scott Deakin University, Australia	S12-2Sarcopenia as a potential cause and consequence of T2DM and interventions to improve musculoskeletal and metabolic health
Jiyeon Baek University of Ulsan, Korea	S12-3How to evaluate sarcopenia in patients with type 2 diabetes
Eugene Han Keimyung University, Korea	S12-4Effects of anti-diabetic drugs on sarcopenia: best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia

Main symposia